Literature DB >> 11372202

Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media.

J Malina1, O Novakova, B K Keppler, E Alessio, V Brabec.   

Abstract

Modifications of natural DNA by three anticancer heterocyclic ruthenium(III) compounds were studied by methods of molecular biophysics. These methods included DNA binding studies using atomic absorption spectrophotometry, inhibition of restriction endonucleases, mapping of DNA adducts by transcription assay, interstrand cross-linking employing gel electrophoresis under denaturing conditions, DNA unwinding studied by gel electrophoresis, circular dichroism analysis of the B-->Z transition in DNA, and DNA melting curves measured by absorption spectrophotometry. The results indicate that the complexes HIm[trans-Cl4Im2RuIII], HInd[trans-Cl4Ind2RuIII], and Na[trans-Cl4Im(Me2SO)RuIII] (Im and Ind stand for imidazole and indazole, respectively) coordinate irreversibly to DNA. Their DNA binding mode is, however, different from that of cisplatin. Interestingly, Na[trans-Cl4Im(Me2SO)RuIII] binds to DNA considerably faster than the other two ruthenium compounds and cisplatin. In addition, when Na[trans-Cl4Im(Me2SO)RuIII] binds to DNA it exhibits an enhanced base sequence specificity in comparison with the other two ruthenium complexes. Na[trans-Cl4Im(Me2SO)RuIII] also forms bifunctional intrastrand adducts on double-helical DNA which are capable of terminating RNA synthesis in vitro, while the capability of the other two ruthenium compounds to form such adducts is markedly lower. This observation has been interpreted to mean that the bifunctional adducts of HInd[trans-Cl4Ind2RuIII] and Na[trans-Cl4Im2RuIII] formed on rigid double-helical DNA are sterically more crowded by their octahedral geometry than those of Na[trans-Cl4Im(Me2SO)RuIII]. In addition, the adducts of all three ruthenium compounds affect the conformation of DNA, Na[trans-Cl4Im(Me2SO)RuIII] being most effective. It has been suggested that the altered DNA binding mode of ruthenium compounds in comparison with cisplatin might be an important factor responsible for the altered cytostatic activity of this class of ruthenium compounds in tumor cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11372202     DOI: 10.1007/s007750100223

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  11 in total

Review 1.  Redox activation of metal-based prodrugs as a strategy for drug delivery.

Authors:  Nora Graf; Stephen J Lippard
Journal:  Adv Drug Deliv Rev       Date:  2012-01-25       Impact factor: 15.470

2.  Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.

Authors:  Alethia A Hostetter; Michelle L Miranda; Victoria J DeRose; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2011-07-08       Impact factor: 3.358

3.  Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.

Authors:  Michael Groessl; Yury O Tsybin; Christian G Hartinger; Bernhard K Keppler; Paul J Dyson
Journal:  J Biol Inorg Chem       Date:  2010-03-07       Impact factor: 3.358

4.  Reactions of Ru(III)-drugs KP1019 and KP418 with guanine, 2'-deoxyguanosine and guanosine: a DFT study.

Authors:  Pramod Kumar Shah; Nihar R Jena; Pradeep Kumar Shukla
Journal:  J Mol Model       Date:  2022-09-05       Impact factor: 2.172

5.  Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

Authors:  Naniye Cetinbas; Michael I Webb; Joshua A Dubland; Charles J Walsby
Journal:  J Biol Inorg Chem       Date:  2009-08-26       Impact factor: 3.358

6.  Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.

Authors:  A Bergamo; L Messori; F Piccioli; M Cocchietto; G Sava
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850

Review 7.  Organometallic anticancer compounds.

Authors:  Gilles Gasser; Ingo Ott; Nils Metzler-Nolte
Journal:  J Med Chem       Date:  2010-11-15       Impact factor: 7.446

8.  DNA Damage Response Checkpoint Activation Drives KP1019 Dependent Pre-Anaphase Cell Cycle Delay in S. cerevisiae.

Authors:  Lindsey A Bierle; Kira L Reich; Braden E Taylor; Eliot B Blatt; Sydney M Middleton; Shawnecca D Burke; Laura K Stultz; Pamela K Hanson; Janet F Partridge; Mary E Miller
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

9.  Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.

Authors:  L Morbidelli; S Donnini; S Filippi; L Messori; F Piccioli; P Orioli; G Sava; M Ziche
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

10.  DNA-metallodrugs interactions signaled by electrochemical biosensors: an overview.

Authors:  Mauro Ravera; Graziana Bagni; Marco Mascini; Domenico Osella
Journal:  Bioinorg Chem Appl       Date:  2007       Impact factor: 7.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.